These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21484381)

  • 1. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.
    Lopci E; Chiti A; Castellani MR; Pepe G; Antunovic L; Fanti S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1():S28-40. PubMed ID: 21484381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?
    Walrand S; Flux GD; Konijnenberg MW; Valkema R; Krenning EP; Lhommel R; Pauwels S; Jamar F
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1():S57-68. PubMed ID: 21484382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matched pairs for radionuclide-based imaging and therapy.
    Bockisch A
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1():S1-3. PubMed ID: 21484377
    [No Abstract]   [Full Text] [Related]  

  • 5. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
    Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
    Boucek JA; Turner JH
    Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
    D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
    Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
    Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
    Bardiès M; Buvat I
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
    Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
    Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
    Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
    Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
    Sgouros G; Hobbs RF; Atkins FB; Van Nostrand D; Ladenson PW; Wahl RL
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S41-7. PubMed ID: 21484384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.
    Howard DM; Kearfott KJ; Wilderman SJ; Dewaraja YK
    Cancer Biother Radiopharm; 2011 Oct; 26(5):615-21. PubMed ID: 21939358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.